Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as IM-1021, -1021
1021 · 1 trial · 2 indications
Type, frequency, seriousness, and severity of adverse events (AEs) graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) criteria version 5.0, including serious adverse events (SAEs), AEs of interest (AEI), AEs leading to discontinuation, and deaths
Type, frequency, seriousness, and severity of AEs graded using the NCI-CTCAE v6.0, including SAEs, AEIs, AEs leading to discontinuation, and deaths
| Arm | Type | Description |
|---|---|---|
| Part A: IM-1021 Dose Escalation | EXPERIMENTAL | IM-1021 given into the vein (IV; intravenously) |
| Part B: IM-1021 Monotherapy Dose Expansion | EXPERIMENTAL | IM-1021 given into the vein (IV; intravenously) |
| Name | Type | Description |
|---|---|---|
| IM-1021 | DRUG | IM-1021 is an antibody-drug conjugate |
Inclusion Criteria: 1. Informed consent signed by the participant prior to conducting study-specific procedures 2. ≥18 years of age 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 4. Histological or cytological diagnosis of: Part A: advanced B-cell lymphomas or sol...
IM-1021 is an investigational monoclonal antibody being developed for the treatment of solid malignancies. It is currently being studied in a Phase 1 clinical trial in participants with advanced cancer, including solid and hematologic malignancies.
IM-1021 targets ROR1, a receptor tyrosine kinase expressed on the surface of certain cancer cells. As an antibody-drug conjugate, it is designed to deliver a cytotoxic payload to ROR1-positive tumor cells.
IM-1021 is being developed by Immunome, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol IMNM. The company is conducting a Phase 1 clinical trial to evaluate the drug in patients with advanced cancer.
IM-1021 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1 study is currently recruiting participants with advanced cancer.
IM-1021 is being evaluated in a Phase 1 study (NCT06823167) titled 'A Phase 1 Study of IM-1021 in Participants With Advanced Cancer.' The trial is recruiting up to 117 participants across the United States, Denmark, France, and Spain.
Yes, IM-1021 is also known as -1021. Both names refer to the same investigational antibody-drug conjugate targeting ROR1, developed by Immunome, Inc. for the treatment of advanced solid malignancies.